Please try another search
For the three months ended 31 March 2022, Genesystem Co Ltd revenues decreased 35% to W1.94B. Net loss totaled W593.3M vs. income of W897.1M. Revenues reflect Asia (Region) segment decrease of 75% to W571.7M, South Korea (Country) segment decrease of 85% to W66.6M. Net loss reflects Gain on Foreign Currency Translation decrease of 94% to W22.5M (income), Salaries & Wages increase of 53% to W484.7M (expense).
Period Ending: | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 |
---|---|---|---|---|
Total Revenue | 472.79 | 735.71 | 496.17 | 483.21 |
Gross Profit | -262.24 | 87.35 | -77.85 | -8.14 |
Operating Income | -2579.51 | -2274.25 | -1936.39 | -1684.36 |
Net Income | -2182.49 | -4846.8 | -1963.58 | -1608.65 |
Period Ending: | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 |
---|---|---|---|---|
Total Assets | 39216.93 | 41183.1 | 46059.37 | 47947.22 |
Total Liabilities | 6266.13 | 6072.66 | 5926.39 | 5892.6 |
Total Equity | 32950.8 | 35110.44 | 40132.98 | 42054.62 |
Period Ending: | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -1629.07 | -1730.33 | -1688.38 | -2610.47 |
Cash From Investing Activities | -3616.95 | -1143.19 | -5147.49 | 2281.26 |
Cash From Financing Activities | -10.63 | 40.51 | -19.21 | 172.24 |
Net Change in Cash | -5268.31 | -2891.13 | -6833.76 | -121.21 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review